464 related articles for article (PubMed ID: 30471652)
1. All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma.
Dimopoulos MA; Grosicki S; Jędrzejczak WW; Nahi H; Gruber A; Hansson M; Gupta N; Byrne C; Labotka R; Teng Z; Yang H; Grzasko N; Kumar S
Eur J Cancer; 2019 Jan; 106():89-98. PubMed ID: 30471652
[TBL] [Abstract][Full Text] [Related]
2. Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma.
Kumar SK; Grzasko N; Delimpasi S; Jedrzejczak WW; Grosicki S; Kyrtsonis MC; Spencer A; Gupta N; Teng Z; Byrne C; Labotka R; Dimopoulos MA
Br J Haematol; 2019 Feb; 184(4):536-546. PubMed ID: 30460684
[TBL] [Abstract][Full Text] [Related]
3. Ixazomib-based frontline therapy in patients with newly diagnosed multiple myeloma in real-life practice showed comparable efficacy and safety profile with those reported in clinical trial: a multi-center study.
Li J; Bao L; Xia Z; Wang S; Zhou X; Ding K; Zhang W; Yang W; Li B; Fu C; Chen B; Hua L; Wang L; Luo J; Yang Y; Xu T; Wang W; Huang Y; Wu G; Liu P
Ann Hematol; 2020 Nov; 99(11):2589-2598. PubMed ID: 32892275
[TBL] [Abstract][Full Text] [Related]
4. A phase I/II dose-escalation study investigating all-oral ixazomib-melphalan-prednisone induction followed by single-agent ixazomib maintenance in transplant-ineligible newly diagnosed multiple myeloma.
San-Miguel JF; Echeveste Gutierrez MA; Špicka I; Mateos MV; Song K; Craig MD; Bladé J; Hájek R; Chen C; Di Bacco A; Estevam J; Gupta N; Byrne C; Lu V; van de Velde H; Lonial S
Haematologica; 2018 Sep; 103(9):1518-1526. PubMed ID: 29954932
[TBL] [Abstract][Full Text] [Related]
5. Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma.
Facon T; Venner CP; Bahlis NJ; Offner F; White DJ; Karlin L; Benboubker L; Rigaudeau S; Rodon P; Voog E; Yoon SS; Suzuki K; Shibayama H; Zhang X; Twumasi-Ankrah P; Yung G; Rifkin RM; Moreau P; Lonial S; Kumar SK; Richardson PG; Rajkumar SV
Blood; 2021 Jul; 137(26):3616-3628. PubMed ID: 33763699
[TBL] [Abstract][Full Text] [Related]
6. Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma.
Kumar SK; Buadi FK; LaPlant B; Halvorson A; Leung N; Kapoor P; Dingli D; Gertz MA; Go RS; Bergsagel PL; Lin Y; Dispenzieri A; Hwa YL; Fonder A; Hobbs M; Fonseca R; Hayman SR; Stewart AK; Lust JA; Mikhael J; Gonsalves W; Reeder C; Skacel T; Rajkumar SV; Lacy MQ
Blood Cancer J; 2018 Jul; 8(8):70. PubMed ID: 30061664
[TBL] [Abstract][Full Text] [Related]
7. Twice-weekly ixazomib in combination with lenalidomide-dexamethasone in patients with newly diagnosed multiple myeloma.
Richardson PG; Hofmeister CC; Rosenbaum CA; Htut M; Vesole DH; Berdeja JG; Liedtke M; Chari A; Smith SD; Lebovic D; Raje N; Byrne C; Liao E; Gupta N; Bacco AD; Estevam J; Berg D; Baz R
Br J Haematol; 2018 Jul; 182(2):231-244. PubMed ID: 29938772
[TBL] [Abstract][Full Text] [Related]
8. Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies.
Dimopoulos MA; Laubach JP; Echeveste Gutierrez MA; Grzasko N; Hofmeister CC; San-Miguel JF; Kumar S; Labotka R; Lu V; Berg D; Byrne C; Teng Z; Liu G; van de Velde H; Richardson PG
Eur J Haematol; 2019 Jun; 102(6):494-503. PubMed ID: 30943323
[TBL] [Abstract][Full Text] [Related]
9. Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance.
Kumar SK; Berdeja JG; Niesvizky R; Lonial S; Laubach JP; Hamadani M; Stewart AK; Hari P; Roy V; Vescio R; Kaufman JL; Berg D; Liao E; Rajkumar SV; Richardson PG
Leukemia; 2019 Jul; 33(7):1736-1746. PubMed ID: 30696949
[TBL] [Abstract][Full Text] [Related]
10. Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial.
Dimopoulos MA; Gay F; Schjesvold F; Beksac M; Hajek R; Weisel KC; Goldschmidt H; Maisnar V; Moreau P; Min CK; Pluta A; Chng WJ; Kaiser M; Zweegman S; Mateos MV; Spencer A; Iida S; Morgan G; Suryanarayan K; Teng Z; Skacel T; Palumbo A; Dash AB; Gupta N; Labotka R; Rajkumar SV;
Lancet; 2019 Jan; 393(10168):253-264. PubMed ID: 30545780
[TBL] [Abstract][Full Text] [Related]
11. Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Moreau P; Masszi T; Grzasko N; Bahlis NJ; Hansson M; Pour L; Sandhu I; Ganly P; Baker BW; Jackson SR; Stoppa AM; Simpson DR; Gimsing P; Palumbo A; Garderet L; Cavo M; Kumar S; Touzeau C; Buadi FK; Laubach JP; Berg DT; Lin J; Di Bacco A; Hui AM; van de Velde H; Richardson PG;
N Engl J Med; 2016 Apr; 374(17):1621-34. PubMed ID: 27119237
[TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
Kumar SK; Berdeja JG; Niesvizky R; Lonial S; Laubach JP; Hamadani M; Stewart AK; Hari P; Roy V; Vescio R; Kaufman JL; Berg D; Liao E; Di Bacco A; Estevam J; Gupta N; Hui AM; Rajkumar V; Richardson PG
Lancet Oncol; 2014 Dec; 15(13):1503-1512. PubMed ID: 25456369
[TBL] [Abstract][Full Text] [Related]
13. Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma.
Ludwig H; Poenisch W; Knop S; Egle A; Schreder M; Lechner D; Hajek R; Gunsilius E; Krenosz KJ; Petzer A; Weisel K; Niederwieser D; Einsele H; Willenbacher W; Melchardt T; Greil R; Zojer N
Br J Cancer; 2019 Oct; 121(9):751-757. PubMed ID: 31558804
[TBL] [Abstract][Full Text] [Related]
14. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study.
Hou J; Jin J; Xu Y; Wu D; Ke X; Zhou D; Lu J; Du X; Chen X; Li J; Liu J; Gupta N; Hanley MJ; Li H; Hua Z; Wang B; Zhang X; Wang H; van de Velde H; Richardson PG; Moreau P
J Hematol Oncol; 2017 Jul; 10(1):137. PubMed ID: 28683766
[TBL] [Abstract][Full Text] [Related]
15. Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study.
Kersten MJ; Amaador K; Minnema MC; Vos JMI; Nasserinejad K; Kap M; Kastritis E; Gavriatopoulou M; Kraan W; Chamuleau MED; Deeren D; Tick LW; Doorduijn JK; Offner F; Böhmer LH; Liu RD; Pals ST; Dimopoulos MA
J Clin Oncol; 2022 Jan; 40(1):40-51. PubMed ID: 34388022
[TBL] [Abstract][Full Text] [Related]
16. Assessment of prolonged proteasome inhibition through ixazomib-based oral regimen on newly diagnosed and first-relapsed multiple myeloma: A real-world Chinese cohort study.
Liu A; Yu H; Hou R; Zhu Z; Zhuang JL; Bao L; Li Z; Liu L; Hua L; Ma Y; Gao D; Jin A; Suo X; Yang W; Bai Y; Fu R; Zheng D; Chen W
Cancer Med; 2024 May; 13(9):e7177. PubMed ID: 38686615
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of continuous ixazomib, thalidomide and dexamethasone for relapsed and/or refractory multiple myeloma: the Australasian Myeloma Research Consortium (AMaRC) 16-02 trial.
Bergin K; Yuen F; Wallington-Beddoe C; Kalff A; Sirdesai S; Reynolds J; Spencer A
Br J Haematol; 2021 Aug; 194(3):580-586. PubMed ID: 33991421
[TBL] [Abstract][Full Text] [Related]
18. Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma.
Kaiser M; Beksaç M; Gulbrandsen N; Schjesvold F; Hájek R; Moreau P; de Arriba de la Fuente F; Mateos MV; West S; Spencer A; Rajkumar SV; Suryanarayan K; Czorniak M; Li C; Teng Z; Labotka R; Dimopoulos MA
Ann Hematol; 2020 Aug; 99(8):1793-1804. PubMed ID: 32613281
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
20. [Clinical Efficacy and Safety of Ixazomib-Containing Regimens in the Treatment of Patients with Multiple Myeloma].
Chen R; Xue LG; Zhou H; Jia T; Cai ZM; Zhu YX; Miao L; Wei JF; Zhao LD; Mao JP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):483-492. PubMed ID: 38660856
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]